UNSPSC 51171655: Sodium picosulfate

This classification denotes a laxative with the molecular formula C18H13NO8S2.2Na, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier LR57574HN8, chemically known as 4,4-(2-pyridylmethylene)diphenolbis(hydrogen sulfate) (ester) disodium salt but more generally known as picosulfate sodium, which bears U.S. NIH Compound Identifier 68654. European Medicines Agency schedules Picosulfate sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10569MIG.

The term PICOSULFATE SODIUM is an International Non-Proprietary Name. World Health Organization schedules picosulfate sodium in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary.

UNSPSC 51171655 Sodium picosulfate, a Commodity code, encompasses pharmaceutical products and related testing services procured by state and local governments for corrections, healthcare, and pharmacy benefit programs. Recent state and local solicitations under this code reflect a mix of specimen collection and drug testing services, direct-to-manufacturer pharmacy initiatives, and multi-source generic pharmaceutical supply agreements. Issuing bodies include county corrections departments, state health and human services commissions, and multi-state cooperative purchasing alliances administering contracts on behalf of state agencies and local government facilities. The scope spans immunoassay and confirmatory drug screening (including LC/MS/MS and GC/MS protocols), oral fluid and hair testing, pharmacy benefit management through direct manufacturer relationships, and supply of generic multi-source pharmaceuticals and over-the-counter products through authorized wholesalers.

Recent activity centers in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, plus optional renewals to five years total; the scope includes staffing two collection sites and performing approximately 25,031 annual tests across multiple panel configurations. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage procurement planning for direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with awards effective July 1, 2026 and a two-year contract term for new responders.